Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$52.00 USD
-0.40 (-0.76%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $52.02 +0.02 (0.04%) 7:34 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 161 - 180 ( 192 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:12 Update - Insulin Pump Setting Data ADA June 8-12 to be Major Catalyst
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Believe Selloff Over Done - Positive Catalysts Ahead to Outweigh Potential Risks
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of April 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Herceptin SC HannaH Study Results Positive - Reiterate OUTPERFORM and BEST IDEA
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Update - More to Come - Reiterate OUTPERFORM and Best Ideas Recommendation
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: March 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ViroPharma Manufacturing Setback Unlikely to Affect HALO Partnership - Commitment to SC Cinryze with HALO''s rHuPH20 a High Priority in 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Roche Annual Call Takeaways - Herceptin SC Phase III Data March - MabThera Data 2012; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
February 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase II Data for Cinryze in Combination With rHuPH20 - Insulin Pump Data Expected Q1:12
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
December 2011 Potential Milestones & Key Events - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expert Call Highlights - HALO''s Hylenex Insulin Pump Opportunity "A Game Changer
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Adding to Best Ideas List; Insulin Opportunity Under the Radar and Undervalued
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase II Diabetes Data Could Provide Partnership and Upside, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase III Data for SC Herceptin - Increasing Price Target to $14 from $10 per Share; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.